Joyce A. O’Shaughnessy, MD
Although HER2-positive breast cancer is an aggressive disease historically associated with high relapse and mortality rates, HER2-targeted therapies have revolutionized treatment and led to significantly improved outcomes for many patients.1
Findings from recently reported studies have helped refine established therapeutic regimens and identify subsets of patients with early-stage disease who would benefit from new approaches, according to a panel of breast cancer experts.
, panel members discussed the use of HER2-targeted therapies in patients with early-stage HER2-positive breast cancer in the neoadjuvant and adjuvant settings. They provided their insights on study results reported during the 2018 San Antonio Breast Cancer Symposium (SABCS) and on developments in the field that have enabled even more women to achieve improved outcomes.
AC-THP Versus TCHP
... to read the full story